Background Inhibition of sodium-glucose cotransporter-2 (SGLT2) has received remarkable
attention due to the beneficial effects observed in diabetes mellitus, heart failure, and kidney …

The nucleotide-binding domain-like receptor protein 3 (NLRP3) inflammasome in the kidney
and the heart is increasingly being suggested to play a key role in mediating inflammation …

Aims To investigate in-hospital and long-term prognosis in T2DM patients presenting with
acute myocardial infarction (AMI) treated with SGLT2-I versus other oral anti-diabetic agents …

This study aimed at investigating the SGLT2 expression in human cardiomyocytes. Human
studies evaluating cardiomyocyte SGLT2s expression are limited. To better clarify this issue …

Background It has been proven that sodium-glucose co-transporter 2 inhibitors (SGLT2is)
improve the prognosis of patients with heart failure, independent of the presence of diabetes …

Type 2 diabetes mellitus (T2DM) is a leading risk factor for cardiovascular complications
around the globe and one of the most common medical conditions. Atrial fibrillation (AF) is …

Diabetes mellitus (DM) and heart failure (HF) are frequently encountered afflictions that are
linked by a common pathophysiologic background. According to landmark studies, those …

(1) Background: Sodium-glucose co-transporter-2 (SGLT-2) inhibitors constitute a novel
drug class with remarkable cardiovascular benefits for patients with chronic heart failure …

Heart failure with preserved ejection fraction (HFpEF) is highly prevalent and associated
with worse cardiovascular outcomes. The pathophysiology of HFpEF mostly relies on the …

Under the term cardiorenal syndrome (CRS) falls an increasing number of patients who
present with combined heart and kidney dysfunction. Despite the increasing knowledge …